“We are providing the medicine at no profit to Gilead, and in enough supply to reach up to two million people in low- and lower-middle-income countries ahead of generic lenacapavir becoming available,”

Daniel O’Day · said date not stated · reported 2025-07-14

Gilead reached an agreement with the Global Fund to provide lenacapavir at cost to low- and lower-middle-income countries.